Free tool
Drug Trial Radar: Psychiatry
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
907
Completed, industry sponsors, Psychiatry, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed907
907 trials
Showing 1 to 25, recently updated first.
- Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive DisorderPivotal-lookingCompleted
Biohaven Pharmaceuticals, Inc.Industry
NCT04641143 · 456 participants · Start Dec 22, 2020 · Primary completion Oct 27, 2025
Drug: Troriluzole; Placebo · For: Obsessive-Compulsive Disorder
Sites: Chandler, Arizona; Phoenix, Arizona; Bellflower, California · 73 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04513912 · 757 participants · Start Sep 15, 2020 · Primary completion Oct 3, 2023
Drug: Seltorexant; Matching placebo to Seltorexant and 2 more · For: Depressive Disorder, Major
Sites: Birmingham, Alabama; Tucson, Arizona; Culver City, California · 175 sites in all
- Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)Pivotal-lookingCompleted
VistaGen Therapeutics, Inc.Industry
NCT06615557 · 238 participants · Start Sep 16, 2024 · Primary completion Apr 21, 2026
Drug: Fasedienol Nasal Spray; Placebo Nasal Spray · For: Social Anxiety Disorder (SAD)
Sites: Phoenix, Arizona; Little Rock, Arkansas; Bellflower, California · 26 sites in all
- Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)Pivotal-lookingCompleted
VistaGen Therapeutics, Inc.Industry
NCT06358651 · 238 participants · Start Mar 28, 2024 · Primary completion Oct 31, 2025
Drug: Fasedienol Nasal Spray; Placebo Nasal Spray · For: Social Anxiety Disorder
Sites: Phoenix, Arizona; Fayetteville, Arkansas; Little Rock, Arkansas · 24 sites in all
- The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With DepressionPivotal-lookingCompleted
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT06827431 · 786 participants · Start Feb 21, 2025 · Primary completion Jul 14, 2026
Drug: Ammoxetine; Ammoxetine and 2 more · For: Major Depressive Disorder (MDD)
Sites: Beijing, China; Shanghai, China
- "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"Pivotal-lookingCompleted
Cybin IRL LimitedIndustry
NCT06564818 · 223 participants · Start Dec 17, 2024 · Primary completion Sep 4, 2026
Drug: CYB003; Placebo · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Tucson, Arizona; Bellflower, California · 45 sites in all
- A Study of Adjunctive Aripiprazole in Patients With Major Depressive DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00095823 · 1,200 participants · Start Jun 2004 · Primary completion Aug 2006
Drug: Antidepressant + Placebo; Antidepressant + Aripiprazole · For: Major Depressive Disorder
Sites: Garden Grove, California; Northridge, California; Washington D.C., District of Columbia · 20 sites in all
- Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute SchizophreniaPivotal-lookingCompleted
Vanda PharmaceuticalsIndustry
NCT00254202 · 593 participants · Start Nov 18, 2005 · Primary completion Sep 26, 2006
Drug: Iloperidone; Ziprasidone and 1 more · For: Schizophrenia
Sites: Little Rock, Arkansas; Anaheim, California; Cerritos, California · 42 sites in all
- Lumateperone for the Prevention of Relapse in Patients With SchizophreniaPivotal-lookingCompleted
Intra-Cellular Therapies, Inc.Industry
NCT04959032 · 592 participants · Start Jul 8, 2021 · Primary completion Jul 25, 2024
Drug: Lumateperone 42 mg; Placebo · For: Schizophrenia
Sites: Little Rock, Arkansas; Bellflower, California; Cerritos, California · 43 sites in all
- A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With SchizophreniaPivotal-lookingCompleted
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT05326347 · 247 participants · Start May 31, 2022 · Primary completion Aug 26, 2025
Drug: OPC-34712FUM/ Brexpiprazole fumarate · For: Schizophrenia
Sites: Kure-shi, Japan
- Dexmedetomidine in the Treatment of Agitation Associated With Bipolar DisorderPivotal-lookingCompleted
BioXcel Therapeutics IncIndustry
NCT04276883 · 380 participants · Start Feb 24, 2020 · Primary completion May 21, 2020
Drug: Sublingual film containing Dexmedetomidine (BXCL501); Placebo Film · For: Agitation Associated With Bipolar Disorder; Agitation,Psychomotor; Bipolar Disorder
Sites: Little Rock, Arkansas; Cerritos, California; Culver City, California · 15 sites in all
- Dexmedetomidine in the Treatment of Agitation Associated With SchizophreniaPivotal-lookingCompleted
BioXcel Therapeutics IncIndustry
NCT04268303 · 380 participants · Start Jan 24, 2020 · Primary completion May 6, 2020
Drug: Sublingual film containing dexmedetomidine (BXCL501); Placebo Film · For: Agitation; Schizophrenia; Schizo Affective Disorder and 2 more
Sites: Little Rock, Arkansas; Cerritos, California; Culver City, California · 15 sites in all
- Efficacy, Safety, and Tolerability of COMP360 in Participants With TRDPivotal-lookingCompleted
COMPASS PathwaysIndustry
NCT05624268 · 258 participants · Start Jan 24, 2023 · Primary completion May 28, 2025
Drug: Psilocybin · For: Treatment Resistant Depression
Sites: Tuscon, Arizona; Culver City, California; Garden Grove, California · 40 sites in all
- Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)Pivotal-lookingCompleted
BioXcel Therapeutics IncIndustry
NCT05658510 · 452 participants · Start Nov 21, 2022 · Primary completion Aug 15, 2025
Drug: BXCL501; Matching Placebo · For: Agitation,Psychomotor; Bipolar I Disorder; Bipolar II Disorder and 3 more
Sites: Bellflower, California; Cerritos, California; Culver City, California · 24 sites in all
- An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaPivotal-lookingCompleted
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyBristol Myers Squibb (BMY)
NCT05304767 · 290 participants · Start Mar 7, 2022 · Primary completion Mar 25, 2026
Drug: Xanomeline and Trospium Chloride Capsules · For: Schizophrenia
Sites: Phoenix, Arizona; Little Rock, Arkansas; Anaheim, California · 94 sites in all
- Study of Lumateperone in the Treatment of Patients With Bipolar ManiaPivotal-lookingCompleted
Intra-Cellular Therapies, Inc.Industry
NCT06462612 · 351 participants · Start Jul 17, 2024 · Primary completion May 15, 2026
Drug: Lumateperone; Placebo · For: Bipolar Disorder, Manic
Sites: Bentonville, Arkansas; Little Rock, Arkansas; Anaheim, California · 35 sites in all
- Study of Lumateperone in the Acute Treatment of Patients With Bipolar ManiaPivotal-lookingCompleted
Intra-Cellular Therapies, Inc.Industry
NCT06462586 · 354 participants · Start Jun 19, 2024 · Primary completion Feb 24, 2026
Drug: Lumateperone; Placebo · For: Bipolar Disorder, Manic
Sites: Rogers, Arkansas; Bellflower, California; Culver City, California · 42 sites in all
- A Study of Adjunctive Aripiprazole in Participants With Major Depressive DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00095758 · 1,151 participants · Start Sep 1, 2004 · Primary completion Dec 1, 2006
Drug: Antidepressant + Placebo; Antidepressant + Aripiprazole · For: Major Depressive Disorder
Sites: Beverly Hills, California; Burbank, California; National City, California · 28 sites in all
- A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.Pivotal-lookingCompleted
Luye Pharma Group Ltd.Industry
NCT05970510 · 555 participants · Start Aug 4, 2023 · Primary completion Jul 31, 2025
Drug: Toludesvenlafaxine Hydrochloride Sustained-release Tablet 80mg; Toludesvenlafaxine Hydrochloride Sustained-release Tablet 160mg and 1 more · For: Generalized Anxiety Disorder
Sites: Beijing, China
- Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive DisorderPivotal-lookingCompleted
Neumora Therapeutics, Inc.Industry
NCT06058039 · 422 participants · Start Dec 21, 2023 · Primary completion May 4, 2026
Drug: NMRA-335140; Placebo · For: Major Depressive Disorder
Sites: Cerritos, California; Irvine, California; Long Beach, California · 71 sites in all
- Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderPivotal-lookingCompleted
Neumora Therapeutics, Inc.Industry
NCT06058013 · 430 participants · Start Dec 20, 2023 · Primary completion May 6, 2026
Drug: NMRA-335140; Placebo · For: Major Depressive Disorder
Sites: Encino, California; Garden Grove, California; Los Alamitos, California · 74 sites in all
- Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.Pivotal-lookingCompleted
Cingulate TherapeuticsIndustry
NCT05631626 · 26 participants · Start Dec 29, 2022 · Primary completion Jun 13, 2023
Drug: CTx-1301 - Dexmethylphenidate 25mg; CTx-1301 - Dexmethylphenidate 37.5mg and 2 more · For: ADHD; ADHD - Combined Type; Attention Deficit Hyperactivity Disorder Combined and 1 more
Sites: Las Vegas, Nevada
- A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHDPivotal-lookingCompleted
Shanghai Ark Biopharmaceutical Co., Ltd.Industry
NCT06359899 · 55 participants · Start May 28, 2024 · Primary completion Jan 6, 2025
Drug: AK0901 capsule; Placebo · For: ADHD
Sites: Beijing, China · 2 sites in all
- Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With SchizophreniaPivotal-lookingCompleted
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyBristol Myers Squibb (BMY)
NCT06572449 · 173 participants · Start Oct 28, 2024 · Primary completion Mar 13, 2025
Drug: KarXT · For: Schizophrenia
Sites: Los Alamitos, California; Riverside, California; Hollywood, Florida · 6 sites in all
- A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With SchizophreniaPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT04092686 · 464 participants · Start Oct 14, 2019 · Primary completion Jun 14, 2023
Drug: SEP-363856 75mg; SEP-363856 100mg and 1 more · For: Schizophrenia
Sites: Rogers, Arkansas; Anaheim, California; Bellflower, California · 53 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.